Skip to content
Our Office +972-8-9301-015 |office@biokine.com
Biokine Therapeutics Logo Biokine Therapeutics Logo Biokine Therapeutics Logo
  • Home
  • About Biokine
    • Company Profile
    • Board of Directors
    • Management Team
  • Pipeline
    • Clinical
    • Pre-clinical
  • News & Events
  • Partnering
  • Contact
  • Home
  • About Biokine
    • Company Profile
    • Board of Directors
    • Management Team
  • Pipeline
    • Clinical
    • Pre-clinical
  • News & Events
  • Partnering
  • Contact

BioLineRx Discloses Positive Correlative Data from Phase 2a AML Study and Mechanism-of-Action Data for BL-8040 Oncology Platform at ASH 2016

Home/Clinical Program BL8040/BioLineRx Discloses Positive Correlative Data from Phase 2a AML Study and Mechanism-of-Action Data for BL-8040 Oncology Platform at ASH 2016
Previous Next

BioLineRx Discloses Positive Correlative Data from Phase 2a AML Study and Mechanism-of-Action Data for BL-8040 Oncology Platform at ASH 2016

developer2021-06-03T06:00:35+00:00
Copyright © 2020-2021 Biokine LTD | All Rights Reserved | Site By: Psik Advertising
FacebookTwitterInstagramPinterest
Page load link
Go to Top